Showing 1 - 2 results of 2 for search 'Taiqiang Yan', query time: 0.01s
Refine Results
-
1
-
2
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial by Xin Sun, Yuan Li, Jie Xu, Wei Guo, Yi Huang, Lu Xie, Jin Gu, Kuisheng Liu, Bingxin Zheng, Tingting Ren, Xiaodong Tang, Taiqiang Yan, Rongli Yang, Kunkun Sun, Danhua Shen
Published 2020-05-01Get full text
Article